Clinical impact of natural killer cell reconstitution after allogeneic hematopoietic transplantation

Seminars in Immunopathology

Volumn 30, Issue 4, 2008, Pages 489-503

  Velardi, Andrea ^a   Ruggeri, Loredana ^a   Mancusi, Antonella ^a   Burchielli, Emanuela ^a   Perruccio, Katia ^a   Aversa, Franco ^a   Martelli, Massimo F ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

Author keywords

Allogeneic hematopoietic transplantation; Alloreactivity; Cancer immunotherapy; Graft versus host disease; Graft versus leukemia effect; Leukemia; Natural killer cells

Indexed keywords

CYCLOSPORIN; GLUCOCORTICOID; IMMUNOSUPPRESSIVE AGENT; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; METHOTREXATE; MONOCLONAL ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; T LYMPHOCYTE ANTIBODY; TACROLIMUS; THYMOCYTE ANTIBODY;

ALLELE; ALLOGENIC BONE MARROW TRANSPLANTATION; ALLOIMMUNITY; BACTERIAL INFECTION; CELL ACTIVATION; CORD BLOOD STEM CELL TRANSPLANTATION; DONOR; DONOR SELECTION; GENE EXPRESSION; GRAFT FAILURE; GRAFT VERSUS HOST REACTION; GRAFT VERSUS LEUKEMIA EFFECT; HLA SYSTEM; HUMAN; LEUKEMIA; MYCOSIS; NATURAL KILLER T CELL; NONHUMAN; PRIORITY JOURNAL; PUVA; REVIEW; SIBLING; STEM CELL TRANSPLANTATION;

ANIMALS; GRAFT REJECTION; GRAFT VS HOST DISEASE; HAPLOTYPES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; KILLER CELLS, NATURAL; LEUKEMIA; TRANSPLANTATION, HOMOLOGOUS;

EID: 57249103326     PISSN: 18632297     EISSN: 18632300     Source Type: Journal    
DOI: 10.1007/s00281-008-0136-1     Document Type: Review

References (115)

1. Anasetti C, Velardi A (2003) Hematopoietic cell transplantation from HLA partially matched related donors. In: Blume K, Forman S, Appelbaum F (eds) Hematopoietic cell transplantation. Blackwell Science, Malden
2. Atkinson K, Fibbe W, Champlin R, Ljungman L, Ritz J, Brenner M (2004) Clinical bone marrow and blood stem cell transplantation, 3rd edn. Cambridge University Press, Cambridge
3. EA Copelan 2006 Hematopoietic stem-cell transplantation N Engl J Med 354 1813 1826
4. HJ Kolb C Schmid AJ Barrett DJ Schendel 2004 Graft-versus-leukemia reactions in allogeneic chimeras Blood 103 767 776
5. Ferrara J, Cooke K, Deeg J (2004) Graft vs host disease, 3rd edn. Marcel Dekker, New York
6. E Goulmy R Schipper J Pool E Blokland JH Falkenburg J Vossen A Gratwohl GB Vogelsang HC van Houwelingen JJ van Rood 1996 Mismatches of minor histocompatibility antigens between HLA-identical donors and recipients and the development of graft-versus-host disease after bone marrow transplantation N Engl J Med 334 281 285
7. W Wang LR Meadows JM den Haan NE Sherman Y Chen E Blokland J Shabanowitz AI Agulnik RC Hendrickson CE Bishop 1995 Human H-Y: a male-specific histocompatibility antigen derived from the SMCY protein Science 269 1588 1590
8. E Goulmy 1997 Human minor histocompatibility antigens: new concepts for marrow transplantation and adoptive immunotherapy Immunol Rev 157 125 140
9. T Mutis E Goulmy 2002 Hematopoietic system-specific antigens as targets for cellular immunotherapy of hematological malignancies Semin Hematol 39 23 31
10. E Spierings E Goulmy 2005 Expanding the immunotherapeutic potential of minor histocompatibility antigens J Clin Invest 115 3397 3400
11. R Szydlo JM Goldman JP Klein RP Gale RC Ash FH Bach BA Bradley JT Casper N Flomenberg JL Gajewski E Gluckman PJ Henslee-Downey JM Hows N Jacobsen HJ Kolb B Lowenberg T Masaoka PA Rowlings PM Sondel DW van Bekkum JJ van Rood MR Vowels MJ Zhang MM Horowitz 1997 Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings J Clin Oncol 15 1767 1777
12. E Petersdorf C Anasetti PJ Martin A Woolfrey A Smith E Mickelson M Malkki MT Lin JA Hansen 2001 Genomics of unrelated-donor hematopoietic cell transplantation Curr Opin Immunol 13 582 589
13. EW Petersdorf JA Hansen PJ Martin A Woolfrey M Malkki T Gooley B Storer E Mickelson A Smith C Anasetti 2001 Major-histocompatibility-complex class I alleles and antigens in hematopoietic-cell transplantation N Engl J Med 345 1794 1800
14. EW Petersdorf TA Gooley C Anasetti PJ Martin AG Smith EM Mickelson AE Woolfrey JA Hansen 1998 Optimizing outcome after unrelated marrow transplantation by comprehensive matching of HLA class I and II alleles in the donor and recipient Blood 92 3515 3520
15. T Sasazuki T Juji Y Morishima N Kinukawa H Kashiwabara H Inoko T Yoshida A Kimura T Akaza N Kamikawaji Y Kodera F Takaku 1998 Effect of matching of class I HLA alleles on clinical outcome after transplantation of hematopoietic stem cells from an unrelated donor. Japan Marrow Donor Program N Engl J Med 339 1177 1185
16. CK Hurley LA Baxter Lowe B Logan C Karanes C Anasetti D Weisdorf DL Confer 2003 National marrow donor program HLA-matching guidelines for unrelated marrow transplants Biol Blood Marrow Transplant 9 610 615
17. UM Saarinen-Pihkala G Gustafsson O Ringden C Heilmann A Glomstein G Lonnerholm J Abrahamsson AN Bekassy H Schroeder L Mellander 2001 No disadvantage in outcome of using matched unrelated donors as compared with matched sibling donors for bone marrow transplantation in children with acute lymphoblastic leukemia in second remission J Clin Oncol 19 3406 3414
18. G La Nasa C Giardini F Argiolu F Locatelli M Arras P De Stefano A Ledda A Pizzati MA Sanna A Vacca G Lucarelli L Contu 2002 Unrelated donor bone marrow transplantation for thalassemia: the effect of extended haplotypes Blood 99 4350 4356
19. M Eapen P Rubinstein MJ Zhang BM Camitta C Stevens MS Cairo SM Davies JJ Doyle J Kurtzberg MA Pulsipher JJ Ortega A Scaradavou MM Horowitz JE Wagner 2006 Comparable long-term survival after unrelated and HLA-matched sibling donor hematopoietic stem cell transplantations for acute leukemia in children younger than 18 months J Clin Oncol 24 145 151
20. E Gluckman HA Broxmeyer AD Auerbach HS Friedman GW Douglas A Devergie H Esperou D Thierry G Socie P Lehn 1989 Hematopoietic reconstitution in a patient with Fanconi's anemia by means of umbilical-cord blood from an HLA-identical sibling N Engl J Med 321 1174 1178
21. JE Wagner JN Barker TE DeFor KS Baker BR Blazar C Eide A Goldman J Kersey W Krivit ML MacMillan PJ Orchard C Peters DJ Weisdorf NK Ramsay SM Davies 2002 Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD34 cell dose and HLA disparity on treatment-related mortality and survival Blood 100 1611 1618
22. MJ Laughlin M Eapen P Rubinstein JE Wagner MJ Zhang RE Champlin C Stevens JN Barker RP Gale HM Lazarus DI Marks JJ van Rood A Scaradavou MM Horowitz 2004 Outcomes after transplantation of cord blood or bone marrow from unrelated donors in adults with leukemia N Engl J Med 351 2265 2275
23. V Rocha M Labopin G Sanz W Arcese R Schwerdtfeger A Bosi N Jacobsen T Ruutu M de Lima J Finke F Frassoni E Gluckman 2004 Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia N Engl J Med 351 2276 2285
24. JN Barker DJ Weisdorf TE DeFor BR Blazar PB McGlave JS Miller CM Verfaillie JE Wagner 2005 Transplantation of 2 partially HLA-matched umbilical cord blood units to enhance engraftment in adults with hematologic malignancy Blood 105 1343 1347
25. Y Reisner N Kapoor D Kirkpatrick MS Pollack S Cunningham-Rundles B Dupont MZ Hodes RA Good RJ O'Reilly 1983 Transplantation for severe combined immunodeficiency with HLA-A,B,D,DR incompatible parental marrow cells fractionated by soybean agglutinin and sheep red blood cells Blood 61 341 348
26. A Fischer P Landais W Friedrich G Morgan B Gerritsen A Fasth F Porta C Griscelli SF Goldman R Levinsky 1990 European experience of bone-marrow transplantation for severe combined immunodeficiency Lancet 336 850 854
27. RH Buckley SE Schiff RI Schiff L Markert LW Williams JL Roberts LA Myers FE Ward 1999 Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency N Engl J Med 340 508 516
28. E Bachar-Lustig N Rachamim HW Li F Lan Y Reisner 1995 Megadose of T cell-depleted bone marrow overcomes MHC barriers in sublethally irradiated mice Nat Med 1 1268 1273
29. F Aversa A Tabilio A Terenzi A Velardi F Falzetti C Giannoni R Iacucci T Zei MP Martelli C Gambelunghe 1994 Successful engraftment of T-cell-depleted haploidentical "three-loci" incompatible transplants in leukemia patients by addition of recombinant human granulocyte colony-stimulating factor-mobilized peripheral blood progenitor cells to bone marrow inoculum Blood 84 3948 3955
30. F Aversa A Tabilio A Velardi I Cunningham A Terenzi F Falzetti L Ruggeri G Barbabietola C Aristei P Latini Y Reisner MF Martelli 1998 Treatment of high-risk acute leukemia with T-cell-depleted stem cells from related donors with one fully mismatched HLA haplotype N Engl J Med 339 1186 1193
31. F Aversa A Velardi A Tabilio Y Reisner MF Martelli 2001 Haploidentical stem cell transplantation in leukemia Blood Rev 15 111 119
32. MF Martelli F Aversa E Bachar-Lustig A Velardi S Reich-Zelicher A Tabilio H Gur Y Reisner 2002 Transplants across human leukocyte antigen barriers Semin Hematol 39 48 56
33. F Aversa A Terenzi A Tabilio F Falzetti A Carotti S Ballanti R Felicini F Falcinelli A Velardi L Ruggeri T Aloisi JP Saab A Santucci K Perruccio MP Martelli C Mecucci Y Reisner MF Martelli 2005 Full haplotype-mismatched hematopoietic stem-cell transplantation: a phase II study in patients with acute leukemia at high risk of relapse J Clin Oncol 23 3447 3454
34. I Volpi K Perruccio A Tosti M Capanni L Ruggeri S Posati F Aversa A Tabilio L Romani MF Martelli A Velardi 2001 Postgrafting administration of granulocyte colony-stimulating factor impairs functional immune recovery in recipients of human leukocyte antigen haplotype-mismatched hematopoietic transplants Blood 97 2514 2521
35. K Perruccio A Tosti E Burchielli F Topini L Ruggeri A Carotti M Capanni E Urbani A Mancusi F Aversa MF Martelli L Romani A Velardi 2005 Transferring functional immune responses to pathogens after haploidentical hematopoietic transplantation Blood 106 4397 4406
36. P Comoli M Labirio S Basso F Baldanti P Grossi M Furione M Vigano R Fiocchi G Rossi F Ginevri B Gridelli A Moretta D Montagna F Locatelli G Gerna R Maccario 2002 Infusion of autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for prevention of EBV-related lymphoproliferative disorder in solid organ transplant recipients with evidence of active virus replication Blood 99 2592 2598
37. G Cudkowicz M Bennett 1971 Peculiar immunobiology of bone marrow allografts. II. Rejection of parental grafts by resistant F 1 hybrid mice J Exp Med 134 1513 1528
38. L Ruggeri M Capanni E Urbani K Perruccio WD Shlomchik A Tosti S Posati D Rogaia F Frassoni F Aversa MF Martelli A Velardi 2002 Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants Science 295 2097 2100
39. LL Lanier 2008 Up on the tightrope: natural killer cell activation and inhibition Nat Immunol 9 495 502
40. S Gasser DH Raulet 2006 Activation and self-tolerance of natural killer cells Immunol Rev 214 130 142
41. WM Yokoyama S Kim 2006 Licensing of natural killer cells by self-major histocompatibility complex class I Immunol Rev 214 143 154
42. P Parham 2006 Taking license with natural killer cell maturation and repertoire development Immunol Rev 214 155 160
43. L Moretta C Bottino D Pende M Vitale MC Mingari A Moretta 2004 Different checkpoints in human NK-cell activation Trends Immunol 25 670 676
44. LL Lanier 2005 NK cell recognition Annu Rev Immunol 23 225 274
45. J Wu Y Song AB Bakker S Bauer T Spies LL Lanier JH Phillips 1999 An activating immunoreceptor complex formed by NKG2D and DAP10 Science 285 730 732
46. AM Jamieson A Diefenbach CW McMahon N Xiong JR Carlyle DH Raulet 2002 The role of the NKG2D immunoreceptor in immune cell activation and natural killing Immunity 17 19 29
47. S Bauer V Groh J Wu A Steinle JH Phillips LL Lanier T Spies 1999 Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA Science 285 727 729
48. D Cosman J Mullberg CL Sutherland W Chin R Armitage W Fanslow M Kubin NJ Chalupny 2001 ULBPs, novel MHC class I-related molecules, bind to CMV glycoprotein UL16 and stimulate NK cytotoxicity through the NKG2D receptor Immunity 14 123 133
49. A Diefenbach AM Jamieson SD Liu N Shastri DH Raulet 2000 Ligands for the murine NKG2D receptor: expression by tumor cells and activation of NK cells and macrophages Nat Immunol 1 119 126
50. A Diefenbach ER Jensen AM Jamieson DH Raulet 2001 Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity Nature 413 165 171
51. A Cerwenka AB Bakker T McClanahan J Wagner J Wu JH Phillips LL Lanier 2000 Retinoic acid early inducible genes define a ligand family for the activating NKG2D receptor in mice Immunity 12 721 727
52. V Groh R Rhinehart H Secrist S Bauer KH Grabstein T Spies 1999 Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB Proc Natl Acad Sci U S A 96 6879 6884
53. CL Sutherland NJ Chalupny K Schooley T VandenBos M Kubin D Cosman 2002 UL16-binding proteins, novel MHC class I-related proteins, bind to NKG2D and activate multiple signaling pathways in primary NK cells J Immunol 168 671 679
54. M Kubin L Cassiano J Chalupny W Chin D Cosman W Fanslow J Mullberg AM Rousseau D Ulrich R Armitage 2001 ULBP1, 2, 3: novel MHC class I-related molecules that bind to human cytomegalovirus glycoprotein UL16, activate NK cells Eur J Immunol 31 1428 1437
55. D Pende P Rivera S Marcenaro CC Chang R Biassoni R Conte M Kubin D Cosman S Ferrone L Moretta A Moretta 2002 Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity Cancer Res 62 6178 6186
56. A Pessino S Sivori C Bottino A Malaspina L Morelli L Moretta R Biassoni A Moretta 1998 Molecular cloning of NKp46: a novel member of the immunoglobulin superfamily involved in triggering of natural cytotoxicity J Exp Med 188 953 960
57. C Cantoni C Bottino M Vitale A Pessino R Augugliaro A Malaspina S Parolini L Moretta A Moretta R Biassoni 1999 NKp44, a triggering receptor involved in tumor cell lysis by activated human natural killer cells, is a novel member of the immunoglobulin superfamily J Exp Med 189 787 796
58. D Pende S Parolini A Pessino S Sivori R Augugliaro L Morelli E Marcenaro L Accame A Malaspina R Biassoni C Bottino L Moretta A Moretta 1999 Identification and molecular characterization of NKp30, a novel triggering receptor involved in natural cytotoxicity mediated by human natural killer cells J Exp Med 190 1505 1516
59. G Ferlazzo ML Tsang L Moretta G Melioli RM Steinman C Munz 2002 Human dendritic cells activate resting natural killer (NK) cells and are recognized via the NKp30 receptor by activated NK cells J Exp Med 195 343 351
60. M Colonna J Samaridis 1995 Cloning of immunoglobulin-superfamily members associated with HLA-C and HLA-B recognition by human natural killer cells Science 268 405 408
61. M Uhrberg NM Valiante BP Shum HG Shilling K Lienert-Weidenbach B Corliss D Tyan LL Lanier P Parham 1997 Human diversity in killer cell inhibitory receptor genes Immunity 7 753 763
62. C Vilches P Parham 2002 KIR: diverse, rapidly evolving receptors of innate and adaptive immunity Annu Rev Immunol 20 217 251
63. A Moretta S Sivori M Vitale D Pende L Morelli R Augugliaro C Bottino L Moretta 1995 Existence of both inhibitory (p58) and activatory (p50) receptors for HLA-C molecules in human natural killer cells J Exp Med 182 875 884
64. R Biassoni A Pessino A Malaspina C Cantoni C Bottino S Sivori L Moretta A Moretta 1997 Role of amino acid position 70 in the binding affinity of p50.1 and p58.1 receptors for HLA-Cw4 molecules Eur J Immunol 27 3095 3099
65. M Vales-Gomez HT Reyburn RA Erskine J Strominger 1998 Differential binding to HLA-C of p50-activating and p58-inhibitory natural killer cell receptors Proc Natl Acad Sci U S A 95 14326 14331
66. CC Winter JE Gumperz P Parham EO Long N Wagtmann 1998 Direct binding and functional transfer of NK cell inhibitory receptors reveal novel patterns of HLA-C allotype recognition J Immunol 161 571 577
67. P Parham 2005 MHC class I molecules and KIRs in human history, health and survival Nat Rev Immunol 5 201 214
68. X Saulquin LN Gastinel E Vivier 2003 Crystal structure of the human natural killer cell activating receptor KIR2DS2 (CD158j) J Exp Med 197 933 938
69. CA Stewart F Laugier-Anfossi F Vely X Saulquin J Riedmuller A Tisserant L Gauthier F Romagne G Ferracci FA Arosa A Moretta PD Sun S Ugolini E Vivier 2005 Recognition of peptide-MHC class I complexes by activating killer immunoglobulin-like receptors Proc Natl Acad Sci USA 102 13224 13229
70. S Kim J Poursine-Laurent SM Truscott L Lybarger YJ Song L Yang AR French JB Sunwoo S Lemieux TH Hansen WM Yokoyama 2005 Licensing of natural killer cells by host major histocompatibility complex class I molecules Nature 436 709 713
71. N Anfossi P Andre S Guia CS Falk S Roetynck CA Stewart V Breso C Frassati D Reviron D Middleton F Romagne S Ugolini E Vivier 2006 Human NK cell education by inhibitory receptors for MHC class I Immunity 25 331 342
72. L Moretta A Moretta 2004 Killer immunoglobulin-like receptors Curr Opin Immunol 16 626 633
73. E Ciccone D Pende O Viale C Di Donato G Tripodi AM Orengo J Guardiola A Moretta L Moretta 1992 Evidence of a natural killer (NK) cell repertoire for (allo) antigen recognition: definition of five distinct NK-determined allospecificities in humans J Exp Med 175 709 718
74. M Colonna EG Brooks M Falco GB Ferrara JL Strominger 1993 Generation of allospecific natural killer cells by stimulation across a polymorphism of HLA-C Science 260 1121 1124
75. NM Valiante M Uhrberg HG Shilling K Lienert-Weidenbach KL Arnett A D'Andrea JH Phillips LL Lanier P Parham 1997 Functionally and structurally distinct NK cell receptor repertoires in the peripheral blood of two human donors Immunity 7 739 751
76. SS Farag TA Fehniger L Ruggeri A Velardi MA Caligiuri 2002 Natural killer cell receptors: new biology and insights into the graft-versus-leukemia effect Blood 100 1935 1947
77. A Velardi L Ruggeri A Moretta L Moretta 2002 NK cells: a lesson from mismatched hematopoietic transplantation Trends Immunol 23 438 444
78. P Parham KL McQueen 2003 Alloreactive killer cells: hindrance and help for haematopoietic transplants Nat Rev Immunol 3 108 122
79. L Ruggeri F Aversa MF Martelli A Velardi 2006 Allogeneic hematopoietic transplantation and natural killer cell recognition of missing self Immunol Rev 214 202 218
80. L Ruggeri M Capanni M Casucci I Volpi A Tosti K Perruccio E Urbani RS Negrin MF Martelli A Velardi 1999 Role of natural killer cell alloreactivity in HLA-mismatched hematopoietic stem cell transplantation Blood 94 333 339
81. K Karre 2002 Immunology. A perfect mismatch Science 295 2029 2031
82. L Ruggeri A Mancusi M Capanni E Urbani A Carotti T Aloisi M Stern D Pende K Perruccio E Burchielli F Topini E Bianchi F Aversa MF Martelli A Velardi 2007 Donor natural killer cell allorecognition of missing self in haploidentical hematopoietic transplantation for acute myeloid leukemia: challenging its predictive value Blood 110 433 440
83. KC Hsu S Chida DE Geraghty B Dupont 2002 The killer cell immunoglobulin-like receptor (KIR) genomic region: gene-order, haplotypes and allelic polymorphism Immunol Rev 190 40 52
84. MJ Pando CM Gardiner M Gleimer KL McQueen P Parham 2003 The protein made from a common allele of KIR3DL1 (3DL1*004) is poorly expressed at cell surfaces due to substitution at positions 86 in Ig domain 0 and 182 in Ig domain 1 J Immunol 171 6640 6649
85. R Thomas E Yamada G Alter MP Martin AA Bashirova PJ Norman M Altfeld P Parham SK Anderson DW McVicar M Carrington 2008 Novel KIR3DL1 alleles and their expression levels on NK cells: convergent evolution of KIR3DL1 phenotype variation? J Immunol 180 6743 6750
86. T Igarashi J Wynberg R Srinivasan B Becknell JP McCoy Jr Y Takahashi DA Suffredini WM Linehan MA Caligiuri RW Childs 2004 Enhanced cytotoxicity of allogeneic NK cells with killer immunoglobulin-like receptor ligand incompatibility against melanoma and renal cell carcinoma cells Blood 104 170 177
87. M Stern L Ruggeri A Mancusi ME Bernardo C de Angelis C Bucher F Locatelli F Aversa A Velardi 2008 Survival after T-cell depleted haploidentical stem cell transplantation is improved using the mother as donor Blood 112 708 710
88. P Hansasuta T Dong H Thananchai M Weekes C Willberg H Aldemir S Rowland-Jones VM Braud 2004 Recognition of HLA-A3 and HLA-A11 by KIR3DL2 is peptide-specific Eur J Immunol 34 1673 1679
89. S Cooley V McCullar R Wangen TL Bergemann S Spellman DJ Weisdorf JS Miller 2005 KIR reconstitution is altered by T cells in the graft and correlates with clinical outcomes after unrelated donor transplantation Blood 106 4370 4376
90. SM Davies L Ruggieri T DeFor JE Wagner DJ Weisdorf JS Miller A Velardi BR Blazar 2002 Evaluation of KIR ligand incompatibility in mismatched unrelated donor hematopoietic transplants. Killer immunoglobulin-like receptor Blood 100 3825 3827
91. EJ Lowe V Turner R Handgretinger EM Horwitz E Benaim GA Hale P Woodard W Leung 2003 T-cell alloreactivity dominates natural killer cell alloreactivity in minimally T-cell-depleted HLA-non-identical paediatric bone marrow transplantation Br J Haematol 123 323 326
92. M Bornhauser R Schwerdtfeger H Martin KH Frank C Theuser G Ehninger 2004 Role of KIR ligand incompatibility in hematopoietic stem cell transplantation using unrelated donors Blood 103 2860 2861
93. SS Farag A Bacigalupo M Eapen C Hurley B Dupont MA Caligiuri C Boudreau G Nelson M Oudshoorn J van Rood A Velardi M Maiers M Setterholm D Confer PE Posch C Anasetti N Kamani JS Miller D Weisdorf SM Davies 2006 The effect of KIR ligand incompatibility on the outcome of unrelated donor transplantation: a report from the center for international blood and marrow transplant research, the European blood and marrow transplant registry, and the Dutch registry Biol Blood Marrow Transplant 12 876 884
94. KC Hsu T Gooley M Malkki C Pinto-Agnello B Dupont JD Bignon M Bornhauser F Christiansen A Gratwohl Y Morishima M Oudshoorn O Ringden JJ van Rood E Petersdorf 2006 KIR ligands and prediction of relapse after unrelated donor hematopoietic cell transplantation for hematologic malignancy Biol Blood Marrow Transplant 12 828 836
95. N Kroger T Binder T Zabelina C Wolschke H Schieder H Renges F Ayuk J Dahlke T Eiermann A Zander 2006 Low number of donor activating killer immunoglobulin-like receptors (KIR) genes but not KIR-ligand mismatch prevents relapse and improves disease-free survival in leukemia patients after in vivo T-cell depleted unrelated stem cell transplantation Transplantation 82 1024 1030
96. T Yabe K Matsuo K Hirayasu K Kashiwase S Kawamura-Ishii H Tanaka A Ogawa M Takanashi M Satake K Nakajima K Tokunaga H Inoko H Saji S Ogawa T Juji T Sasazuki Y Kodera Y Morishima 2008 Donor killer immunoglobulin-like receptor (KIR) genotype-patient cognate KIR ligand combination and antithymocyte globulin preadministration are critical factors in outcome of HLA-C-KIR ligand-mismatched T cell-replete unrelated bone marrow transplantation Biol Blood Marrow Transplant 14 75 87
97. MA Dawson A Spencer 2005 Successful use of haploidentical stem-cell transplantation with KIR mismatch as initial therapy for poor-risk myelodysplastic syndrome J Clin Oncol 23 4473 4474
98. S Giebel F Locatelli T Lamparelli A Velardi S Davies G Frumento R Maccario F Bonetti J Wojnar M Martinetti F Frassoni G Giorgiani A Bacigalupo J Holowiecki 2003 Survival advantage with KIR ligand incompatibility in hematopoietic stem cell transplantation from unrelated donors Blood 102 814 819
99. DW Beelen HD Ottinger S Ferencik AH Elmaagacli R Peceny R Trenschel H Grosse-Wilde 2005 Genotypic inhibitory killer immunoglobulin-like receptor ligand incompatibility enhances the long-term antileukemic effect of unmodified allogeneic hematopoietic stem cell transplantation in patients with myeloid leukemias Blood 105 2594 2600
100. AH Elmaagacli H Ottinger M Koldehoff R Peceny NK Steckel R Trenschel H Biersack H Grosse-Wilde DW Beelen 2005 Reduced risk for molecular disease in patients with chronic myeloid leukemia after transplantation from a KIR-mismatched donor Transplantation 79 1741 1747
101. N Kroger B Shaw S Iacobelli T Zabelina K Peggs A Shimoni A Nagler T Binder T Eiermann A Madrigal R Schwerdtfeger M Kiehl HG Sayer J Beyer M Bornhauser F Ayuk AR Zander DI Marks 2005 Comparison between antithymocyte globulin and alemtuzumab and the possible impact of KIR-ligand mismatch after dose-reduced conditioning and unrelated stem cell transplantation in patients with multiple myeloma Br J Haematol 129 631 643
102. W Leung R Iyengar V Turner P Lang P Bader P Conn D Niethammer R Handgretinger 2004 Determinants of antileukemia effects of allogeneic NK cells J Immunol 172 644 650
103. W Leung R Iyengar B Triplett V Turner FG Behm MS Holladay J Houston R Handgretinger 2005 Comparison of killer Ig-like receptor genotyping and phenotyping for selection of allogeneic blood stem cell donors J Immunol 174 6540 6545
104. B Dupont KC Hsu 2004 Inhibitory killer Ig-like receptor genes and human leukocyte antigen class I ligands in haematopoietic stem cell transplantation Curr Opin Immunol 16 634 643
105. KC Hsu CA Keever-Taylor A Wilton C Pinto G Heller K Arkun RJ O'Reilly MM Horowitz B Dupont 2005 Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes Blood 105 4878 4884
106. KC Hsu C Pinto-Agnello T Gooley M Malkki B Dupont EW Petersdorf 2007 Hematopoietic stem cell transplantation: killer immunoglobulin-like receptor component Tissue Antigens 69 Suppl 1 42 45
107. JS Miller S Cooley P Parham SS Farag MR Verneris KL McQueen LA Guethlein EA Trachtenberg M Haagenson MM Horowitz JP Klein DJ Weisdorf 2007 Missing KIR ligands are associated with less relapse and increased graft-versus-host disease (GVHD) following unrelated donor allogeneic HCT Blood 109 5058 5061
108. S Verheyden R Schots W Duquet C Demanet 2005 A defined donor activating natural killer cell receptor genotype protects against leukemic relapse after related HLA-identical hematopoietic stem cell transplantation Leukemia 19 1446 1451
109. D De Santis A Bishara CS Witt A Nagler C Brautbar S Slavin FT Christiansen 2005 Natural killer cell HLA-C epitopes and killer cell immunoglobulin-like receptors both influence outcome of mismatched unrelated donor bone marrow transplants Tissue Antigens 65 519 528
110. M Cook D Briggs C Craddock P Mahendra D Milligan C Fegan P Darbyshire S Lawson E Boxall P Moss 2006 Donor KIR genotype has a major influence on the rate of cytomegalovirus reactivation following T-cell replete stem cell transplantation Blood 107 1230 1232
111. C Chen M Busson V Rocha ML Appert V Lepage N Dulphy P Haas G Socie A Toubert D Charron P Loiseau 2006 Activating KIR genes are associated with CMV reactivation and survival after non-T-cell depleted HLA-identical sibling bone marrow transplantation for malignant disorders Bone Marrow Transplant 38 437 444
112. MA Cook DW Milligan CD Fegan PJ Darbyshire P Mahendra CF Craddock PA Moss DC Briggs 2004 The impact of donor KIR and patient HLA-C genotypes on outcome following HLA-identical sibling hematopoietic stem cell transplantation for myeloid leukemia Blood 103 1521 1526
113. A Bishara D De Santis CC Witt C Brautbar FT Christiansen R Or A Nagler S Slavin 2004 The beneficial role of inhibitory KIR genes of HLA class I NK epitopes in haploidentically mismatched stem cell allografts may be masked by residual donor-alloreactive T cells causing GVHD Tissue Antigens 63 204 211
114. JY Sun L Gaidulis A Dagis J Palmer R Rodriguez MM Miller SJ Forman D Senitzer 2005 Killer Ig-like receptor (KIR) compatibility plays a role in the prevalence of acute GVHD in unrelated hematopoietic cell transplants for AML Bone Marrow Transplant 36 525 530
115. KL McQueen KM Dorighi LA Guethlein R Wong B Sanjanwala P Parham 2007 Donor-recipient combinations of group A and B KIR haplotypes and HLA class I ligand affect the outcome of HLA-matched, sibling donor hematopoietic cell transplantation Hum Immunol 68 309 323